Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...
Collaboration to fight cancer
Cancer Research UK and UCB SA have announced to advance two cancer antibodies of the Brussels-based biopharma company to the clinical testing stage....
Ethris inks €15m deal with Indian Ciplas
The investment is aimed at establishing a long-term strategic partnership until the end of Q1/2023 between Cipla and Ethris for the development of...
Confo Therapeutics and Lilly partner to advance CFTX-1554
Under the agreement, Confo Therapeutics BV got a $40m upfront and milestone payments totalling $590m for licencing its clinical stage angiotensin II...
Novo Holdings invests into standardisation of LC-MS-based proteomics
Novo Holdings, the investment arm of Nordisk A/S has invested €40m in the eight-years-old clinical proteomics specialist Ecosep Aps to benefit from...
European VCs join US$105m financing of US Mediar Thx
Fibrosis, triggered by inflammation or injury, results in an abnormal production of scar tissue that can lead to organ failure. Luckily, not all...
€72M from Novo´s REPAIR Impact Fund for Group B Streptococcus vaccines
Group B Streptococcus (GBS) colonises globally about 15-25% of women and can cause life-threatening infections in newborns during the first months of...